In patients with multiple myeloma, daratumumab treatment not only led to a systemic increase in the frequency of T cells and T-cell receptor clonality but also led to a decrease in CD38-expressing immune cells, for example, regulatory T cells (Treg) expressing CD38 (10). Here, CD38 is linked to plasma cell myeloma.